(Total Views: 654)
Posted On: 06/06/2019 10:57:27 AM
Post# of 72446
My favorite quote from today’s PR:
“Global pharmaceutical companies have demonstrated a high demand, in deal size and volume, for novel oral IBD drugs—and our goal is to further validate Brilacidin in this space. First-in-human testing using the tablet form should help unlock the tremendous potential in Brilacidin for IBD.”
Oh by the way:
“A Phase 2 trial of Brilacidin as an oral rinse for the prevention of Severe Oral Mucositis (SOM) in patients with Head and Neck Cancer, met its primary and secondary endpoints, including reducing the incidence of SOM. The Company plans to advance Brilacidin oral rinse into Phase 3 development, subject to available financial resources.”
My take is that one of two possibilities are in motion:
Option 1 – Leo is finalizing 2 major partnership deals. One is the B-IBD Term Sheet deal and a separate deal for Brilacidin Oral Rinse for Severe Oral Mucositis (B-OM). BOTH of these deals could be significant.
Option 2 – Leo is finalizing a major B-IBD deal that will provide sufficient funding to advance BOTH B-IBD AND B-OM through phase 3 trials. The first paragraph above supports this possibility. In this scenario IPIX would have the option to secure an even more lucrative license deal after completing a phase 3 or possibly taking B-OM direct to a $600M-$1.2B market and keeping 100% of that annual revenue.
Summary: EITHER option 1 or option 2 will greatly reward IPIX shareholders.
“Global pharmaceutical companies have demonstrated a high demand, in deal size and volume, for novel oral IBD drugs—and our goal is to further validate Brilacidin in this space. First-in-human testing using the tablet form should help unlock the tremendous potential in Brilacidin for IBD.”
Oh by the way:
“A Phase 2 trial of Brilacidin as an oral rinse for the prevention of Severe Oral Mucositis (SOM) in patients with Head and Neck Cancer, met its primary and secondary endpoints, including reducing the incidence of SOM. The Company plans to advance Brilacidin oral rinse into Phase 3 development, subject to available financial resources.”
My take is that one of two possibilities are in motion:
Option 1 – Leo is finalizing 2 major partnership deals. One is the B-IBD Term Sheet deal and a separate deal for Brilacidin Oral Rinse for Severe Oral Mucositis (B-OM). BOTH of these deals could be significant.
Option 2 – Leo is finalizing a major B-IBD deal that will provide sufficient funding to advance BOTH B-IBD AND B-OM through phase 3 trials. The first paragraph above supports this possibility. In this scenario IPIX would have the option to secure an even more lucrative license deal after completing a phase 3 or possibly taking B-OM direct to a $600M-$1.2B market and keeping 100% of that annual revenue.
Summary: EITHER option 1 or option 2 will greatly reward IPIX shareholders.
(15)
(0)
